ALB and Sepsis: The dose chosen by Mira and colleagues in the EARSS study (100 ml of 20% albumin 8 hourly for 3 days) achieved an increase in serum albumin to 25 to 29 g/l [61], raising the possibility that the albumin dose used may have been too low to show definite benefit – although this increase was similar to that reported in the SAFE study subgroup analysis of patients with sepsis, in whom a benefit was reported [54].